

# Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C8A7A9C41CCEN.html>

Date: May 2020

Pages: 1353

Price: US\$ 2,500.00 (Single User License)

ID: C8A7A9C41CCEN

## Abstracts

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia – Pipeline Review, H1 2020, provides an overview of the Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key

players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 5, 60, 67, 3, 8, 60, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 16 and 5 molecules, respectively.

Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Chronic Lymphocytic Leukemia (CLL) - Overview

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics  
Development

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acepodia Biotech Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..1), H1 2020

## Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..2), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

ABL Bio Inc

ACEA Therapeutics Inc

Acepodia Biotech Inc

Acerta Pharma BV

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Aeglea BioTherapeutics Inc

Agenus Inc

AI Therapeutics

Anew Oncology Inc

Apotex Inc

Apra Therapeutics AB

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVM Biotechnology LLC



Bantam Pharmaceutical LLC  
Bayer AG  
BeiGene Ltd  
Beijing GD Initiative Cell Therapy Technology Co Ltd  
Beijing Immunochina Medical Science & Technology Co Ltd  
Beijing Mabworks Biotech Co Ltd  
Bellicum Pharmaceuticals Inc  
BendaRx Corp  
Bio-Path Holdings Inc  
BioIntegrator Ltd  
Bionomics Ltd  
BioNTech SE  
BioXpress Therapeutics SA  
Boryung Pharmaceutical Co Ltd  
Bristol-Myers Squibb Co  
CARsgen Therapeutics Ltd  
CASI Pharmaceuticals Inc  
Catapult Therapeutics BV  
Celldex Therapeutics Inc  
Cellecrta Biosciences Inc  
Cellular Biomedicine Group Inc  
Celularity Inc  
Centaurus Biopharma Co Ltd  
Checkpoint Therapeutics Inc  
Chengdu Brilliant Pharmaceutical Co Ltd  
CrystalGenomics Inc  
Cyclacel Pharmaceuticals Inc  
Cyteir Therapeutics Inc  
Deciphera Pharmaceuticals Inc  
Dizal (Jiangsu) Pharmaceutical Co Ltd  
Eli Lilly and Co  
Ergon Pharmaceuticals LLC  
Eternity Bioscience Inc  
Eureka Therapeutics Inc  
Exinda Therapeutics LLC  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
GeneaMed Ltd  
Genentech Inc

Generium  
Genmab AS  
Gilead Sciences Inc  
GLG Pharma SA  
Grid Therapeutics LLC  
Grupo Ferrer Internacional SA  
Guangzhou BeBetter Medicine Technology Co Ltd  
Hangzhou Hezheng Pharmaceutical Co Ltd  
Hangzhou Minsheng Pharmaceutical Group Co Ltd  
Harrow Health Inc  
Heidelberg Pharma AG  
Helocyte Biosciences Inc  
Hengenix Biotech Inc  
HRAIN Biotechnology Co Ltd  
Hutchison MediPharma Ltd  
Hybrigenics SA  
iBio Inc  
IGM Biosciences Inc  
Iksuda Therapeutics Ltd  
Ildong Pharmaceutical Co Ltd  
Immatics Biotechnologies GmbH  
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd  
ImmuneTarget Inc  
ImmunityBio Inc  
Immunomedics Inc  
Incuron LLC  
Incyte Corp  
Inflection Biosciences Ltd  
InnoCare Pharma Ltd  
Innovative Cellular Therapeutics Co Ltd  
Innovent Biologics Inc  
Invectys SA  
IO Biotech ApS  
Iovance Biotherapeutics Inc  
Johnson & Johnson  
Juno Therapeutics Inc  
Kancera AB  
Kangpu Biopharmaceuticals Ltd  
Karus Therapeutics Ltd

Karyopharm Therapeutics Inc  
Kecellitics Biotech Co Ltd  
LegoChem Biosciences Inc  
LFB SA  
Light Chain Bioscience  
Mabion SA  
MEI Pharma Inc  
MENTRIK Biotech LLC  
Merck & Co Inc  
Merck KGaA  
Millennium Pharmaceuticals Inc  
Miltenyi Biotec GmbH  
MingSight Pharmaceuticals Inc  
Miragen Therapeutics Inc  
MorphoSys AG  
Mustang Bio Inc  
Nanjing Bioheng Biotech Co Ltd  
Nanjing Sanhome Pharmaceutical Co Ltd  
NantKwest Inc  
Nichi-Iko Pharmaceutical Co Ltd  
Nordic Nanovector ASA  
NovalGen Ltd  
Novartis AG  
Nurix Therapeutics Inc  
OncoTartis Inc  
Oncternal Therapeutics  
Ono Pharmaceutical Co Ltd  
Orano Med LLC  
Panorama Research Inc  
PEP-Therapy SAS  
PersonGen Biomedicine Suzhou Co Ltd  
Pfizer Inc  
Pharmapraxis  
PIQUR Therapeutics AG  
Plexxikon Inc  
Precision Biosciences Inc  
Promethera Biosciences SA  
Qurient Co Ltd  
Revitope Oncology Inc

Rhizen Pharmaceuticals SA  
Sanofi  
SFA Therapeutics LLC  
Shanghai GeneChem Co Ltd  
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd  
Shanghai YaKe Biotechnology Inc  
Shanghai Yingli Pharmaceutical Co Ltd  
Sian Wuhan Medical Technology Co Ltd  
Sichuan Haisco Pharmaceutical Co Ltd  
SpecificiT Pharma Inc  
Starton Therapeutics Inc  
Supratek Pharma Inc  
Surface Oncology Inc  
Suzhou Sinovent Pharmaceuticals Co Ltd  
Takeda Pharmaceutical Co Ltd  
Targazyme Inc  
TG Therapeutics Inc  
Tolero Pharmaceuticals Inc  
Trillium Therapeutics Inc  
United BioPharma Inc  
VelosBio Inc  
Verastem Inc  
Viralytics Pty Ltd  
Wuhan Bio-Raid Biotechnology Co Ltd  
XEME BioPharma Inc  
Zhejiang DTRM Biopharma LLC  
Zhejiang Teruisi Pharmaceutical Inc  
ZIOPHARM Oncology Inc

## I would like to order

Product name: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C8A7A9C41CCEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8A7A9C41CCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970